MLL-SEPTIN gene fusions in hematological malignancies

• Type: Another Publication in an International Scientific Journal
• Date: 2011

Authors

cerveira, n (Author) Other; Bizarro, S (Author) Other; Manuel R Teixeira (Author) ICBAS

Journal

Title: Biological Chemistry

Vol. 392

Pages: 713-724

ISSN: 1431-6730

Publisher: Walter De Gruyter

Indexing

ISI Web of Knowledge - 39 Citations

Scopus - 42 Citations

Other information

Authenticus ID: P-002-P8P

DOI: 10.1515/bc.2011.072

Abstract (EN): The mixed lineage leukemia (MLL) locus is involved in more than 60 different rearrangements with a remarkably diverse group of fusion partners in approximately 10% of human leukemias. MLL rearrangements include chromosomal translocations, gene internal duplications, chromosome 11q deletions or inversions and MLL gene insertions into other chromosomes, or vice versa. MLL fusion partners can be classified into four distinct categories: nuclear proteins, cytoplasmatic proteins, histone acetyltransferases and septins. Five different septin genes (SEPT2, SEPT5, SEPT6, SEPT9, and SEPT11) have been identified as MLL fusion partners, giving rise to chimeric fusion proteins in which the N terminus of MLL is fused, in frame, to almost the entire open reading frame of the septin partner gene. The rearranged alleles result from heterogeneous breaks in distinct introns of both MLL and its septin fusion partner, originating distinct gene fusion variants. MLL-SEPTIN rearrangements have been repeatedly identified in de novo and therapy related myeloid neoplasia in both children and adults, and some clinicopathogenetic associations are being uncovered. The fundamental roles of septins in cytokinesis, membrane remodeling and compartmentalization can provide some clues on how abnormalities in the septin cytoskeleton and MLL deregulation could be involved in the pathogenesis of hematological malignancies.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12